In the present study, we assessed the effect of prostate gland size on patient-assessed genitourinary and gastrointestinal (GI) quality of life (QOL) after definitive treatment of prostate adenocarcinoma with proton beam therapy.
Patients and Methods
As a part of a prospective outcome tracking protocol, 81 patients treated at a single center between with proton beam therapy completed the Expanded Prostate Cancer Index Composite (EPIC) questionnaire before treatment and at the follow-up examinations. We reviewed the dosimetric data, reported as Vx (volume of organ receiving x Gy), and patient-reported QOL at 6 months. Genitourinary QOL was assessed using the American Urological Association symptom score and EPIC urinary domain score. GI QOL was assessed using the EPIC GI domain score.
Larger prostate glands were associated with greater bladder V70 (P < .01) and rectal V70 (P < .01). The rectal V70 was < 15% for all patients (range, 4%-13.8%) with the planned treatment volume coverage (percentage of the prescription dose covering 95% of the volume > 95%) maintained. Patients with larger prostates did not have a greater change in their American Urological Association symptom index scores (< 30 cm3, +2.3; 30-49 cm3, +3.2; ≥ 50 cm3, 0.2; P = .06) or urinary domain score (< 30 cm3, −3.6; 30-49 cm3, −3.1; ≥ 50 cm3, +3.8; P = .76) at 6 months after treatment. Also, prostate size was not associated with a change in the EPIC GI domain score at 6 months after treatment (< 30 cm3, −3.7; 30-49 cm3, −1.1; ≥ 50 cm3, −0.55; P = .67).
Definitive proton beam therapy for prostate cancer to a dose of 79.2 Gy resulted in excellent patient-reported urinary and GI QOL, independently of the baseline prostate size. This single-institution finding should be tested further in a multi-institutional study to confirm the potential limited role of androgen deprivation therapy.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Genitourinary Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Cancer statistics, 2014.CA Cancer J Clin. 2014; 64: 9-29
- Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer.Int J Radiat Oncol Biol Phys. 2008; 70: 744-751
- Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer.JAMA. 2010; 303: 1046-1053
- Rectal dose-volume differences using proton radiotherapy and a rectal balloon or water alone for the treatment of prostate cancer.Int J Radiat Oncol Biol Phys. 2007; 69: 1110-1116
- Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09.J Clin Oncol. 2010; 28: 1106-1111
- Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer.JAMA. 2012; 307: 1611-1620
- Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer.Int J Radiat Oncol Biol Phys. 2008; 70: 83-89
- The impact of prostate volume following neoadjuvant androgen deprivation on quality of life and voiding symptoms in patients undergoing permanent prostate brachytherapy.Eur Urol. 2003; 43: 467-472
- Effect of pretreatment prostate volume on urinary quality of life following intensity-modulated radiation therapy for localized prostate cancer.Res Rep Urol. 2013; 5: 29-37
- The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy.Int J Radiat Oncol Biol Phys. 2011; 79: 379-384
- Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy.Urology. 1997; 49: 38-45
- Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation.Cancer Invest. 1995; 13: 8-15
- Proton therapy for prostate cancer treatment employing online image guidance and an action level threshold.Am J Clin Oncol. 2009; 32: 180-186
- Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.Urology. 2000; 56: 899-905
- Quality of life and satisfaction with outcome among prostate-cancer survivors.N Engl J Med. 2008; 358: 1250-1261
- Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial.Int J Radiat Oncol Biol Phys. 2013; 87: 932-938
- Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial.Int J Radiat Oncol Biol Phys. 2002; 53: 1097-1105
- Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer.Int J Radiat Oncol Biol Phys. 2008; 70: 67-74
- Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.JAMA. 2005; 294: 1233-1239
- Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.Lancet Oncol. 2007; 8: 475-487
- Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.J Clin Oncol. 2006; 24: 1990-1996
- Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.Int J Radiat Oncol Biol Phys. 2005; 61: 1019-1034
- Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.Int J Radiat Oncol Biol Phys. 2005; 62: 1297-1308
- Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy.Int J Radiat Oncol Biol Phys. 1994; 29: 755-761
- Changes in treatment volume of hormonally treated and untreated cancerous prostate and its impact on rectal dose.Acta Oncol. 2003; 42: 10-14
- Outcomes in men with large prostates (≥60 cm(3)) treated with definitive proton therapy for prostate cancer.Acta Oncol. 2013; 52: 470-476
- Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.N Engl J Med. 1997; 337: 295-300
- Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy.Int J Radiat Oncol Biol Phys. 2005; 62: 397-405
- Late GI and GU complications in the treatment of prostate cancer.Int J Radiat Oncol Biol Phys. 1997; 37: 3-11
- Quality of life after treatment for localized prostate cancer: differences based on treatment modality.J Urol. 2001; 166: 947-952
- Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.J Clin Oncol. 2003; 21: 3972-3978
Published online: March 18, 2017
Accepted: March 10, 2017
Received in revised form: March 10, 2017
Received: January 18, 2017
© 2017 Elsevier Inc. All rights reserved.